KR20070033982A - 천심련으로부터의 조추출물 - Google Patents
천심련으로부터의 조추출물 Download PDFInfo
- Publication number
- KR20070033982A KR20070033982A KR1020067025043A KR20067025043A KR20070033982A KR 20070033982 A KR20070033982 A KR 20070033982A KR 1020067025043 A KR1020067025043 A KR 1020067025043A KR 20067025043 A KR20067025043 A KR 20067025043A KR 20070033982 A KR20070033982 A KR 20070033982A
- Authority
- KR
- South Korea
- Prior art keywords
- andrographolide
- weight
- deoxy
- extract
- neoandrographolide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Description
Claims (21)
- 천심련(Andrographis paniculata) 추출물의 유효량을 피험자에게 투여하는 것을 포함하는, 그것을 필요로 하는 피험자에서 TNFα의 발현을 억제하는 방법.
- 제1항에 있어서,상기 추출물이 안드로그라폴라이드, 14-데옥시-안드로그라폴라이드, 14-데옥시-11,12-디하이드로겐-안드로그라폴라이드 및 네오안드로그라폴라이드를 포함하는 방법.
- 제2항에 있어서,상기 추출물이 안드로그라폴라이드 2 내지 20중량%, 14-데옥시-안드로그라폴라이드 1 내지 6중량%, 14-데옥시-11,12-디하이드로겐-안드로그라폴라이드 1 내지 12중량% 및 네오안드로그라폴라이드 1 내지 5중량%를 포함하는 방법.
- 제3항에 있어서,상기 추출물이 안드로그라폴라이드 3 내지 8중량%, 14-데옥시-안드로그라폴라이드 3 내지 5중량%, 14-데옥시-11,12-디하이드로겐-안드로그라폴라이드 7 내지 9중량% 및 네오안드로그라폴라이드 2 내지 4중량%를 포함하는 방법.
- 제4항에 있어서,상기 추출물이 안드로그라폴라이드 4.2중량%, 14-데옥시-안드로그라폴라이드 4.4중량%, 14-데옥시-11,12-디하이드로겐-안드로그라폴라이드 8중량% 및 네오안드로그라폴라이드 2.1중량%를 포함하는 방법.
- 천심련 추출물의 유효량을 피험자에게 투여하는 것을 포함하는, 그것을 필요로 하는 피험자에서 IL-1β의 발현을 억제하는 방법
- 제6항에 있어서,상기 추출물이 안드로그라폴라이드, 14-데옥시-안드로그라폴라이드, 14-데옥시-11,12-디하이드로겐-안드로그라폴라이드 및 네오안드로그라폴라이드를 포함하는 방법.
- 제7항에 있어서,상기 추출물이 안드로그라폴라이드 2 내지 20중량%, 14-데옥시-안드로그라폴라이드 1 내지 6중량%, 14-데옥시-11,12-디하이드로겐-안드로그라폴라이드 1 내지 12중량% 및 네오안드로그라폴라이드 1 내지 5중량%를 포함하는 방법.
- 제8항에 있어서,상기 추출물이 안드로그라폴라이드 3 내지 8중량%, 14-데옥시-안드로그라폴 라이드 3 내지 5중량%, 14-데옥시-11,12-디하이드로겐-안드로그라폴라이드 7 내지 9중량% 및 네오안드로그라폴라이드 2 내지 4중량%를 포함하는 방법.
- 제9항에 있어서,상기 추출물이 안드로그라폴라이드 4.2중량%, 14-데옥시-안드로그라폴라이드 4.4중량%, 14-데옥시-11,12-디하이드로겐-안드로그라폴라이드 8중량% 및 네오안드로그라폴라이드 2.1중량%를 포함하는 방법.
- 천심련 추출물의 유효량을 피험자에게 투여하는 것을 포함하는, 그것을 필요로 하는 피험자에서 염증성 장질환(inflammatory bowel disease)을 치료하기 위한 방법.
- 제11항에 있어서,상기 추출물이 안드로그라폴라이드, 14-데옥시-안드로그라폴라이드, 14-데옥시-11,12-디하이드로겐-안드로그라폴라이드 및 네오안드로그라폴라이드를 포함하는 방법.
- 제12항에 있어서,상기 추출물이 안드로그라폴라이드 2 내지 20중량%, 14-데옥시-안드로그라폴라이드 1 내지 6중량%, 14-데옥시-11,12-디하이드로겐-안드로그라폴라이드 1 내지 12중량% 및 네오안드로그라폴라이드 1 내지 5중량%를 포함하는 방법.
- 제13항에 있어서,상기 추출물이 안드로그라폴라이드 3 내지 8중량%, 14-데옥시-안드로그라폴라이드 3 내지 5중량%, 14-데옥시-11,12-디하이드로겐-안드로그라폴라이드 7 내지 9중량% 및 네오안드로그라폴라이드 2 내지 4중량%를 포함하는 방법.
- 제14항에 있어서,상기 추출물이 안드로그라폴라이드 4.2중량%, 14-데옥시-안드로그라폴라이드 4.4중량%, 14-데옥시-11,12-디하이드로겐-안드로그라폴라이드 8중량% 및 네오안드로그라폴라이드 2.1중량%를 포함하는 방법.
- 제11항에 있어서,상기 염증성 장질환이 크론병(Crohn's disease)인 방법.
- 제16항에 있어서,상기 추출물이 안드로그라폴라이드, 14-데옥시-안드로그라폴라이드, 14-데옥시-11,12-디하이드로겐-안드로그라폴라이드 및 네오안드로그라폴라이드를 포함하는 방법.
- 제17항에 있어서,상기 추출물이 안드로그라폴라이드 2 내지 20중량%, 14-데옥시-안드로그라폴라이드 1 내지 6중량%, 14-데옥시-11,12-디하이드로겐-안드로그라폴라이드 1 내지 12중량% 및 네오안드로그라폴라이드 1 내지 5중량%를 포함하는 방법.
- 제11항에 있어서,상기 염증성 장질환이 궤양성 대장염(ulcerative colitis)인 방법.
- 제19항에 있어서,상기 추출물이 안드로그라폴라이드, 14-데옥시-안드로그라폴라이드, 14-데옥시-11,12-디하이드로겐-안드로그라폴라이드 및 네오안드로그라폴라이드를 포함하는 방법.
- 제20항에 있어서,상기 추출물이 안드로그라폴라이드 2 내지 20중량%, 14-데옥시-안드로그라폴라이드 1 내지 6중량%, 14-데옥시-11,12-디하이드로겐-안드로그라폴라이드 1 내지 12중량% 및 네오안드로그라폴라이드 1 내지 5중량%를 포함하는 방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56647704P | 2004-04-28 | 2004-04-28 | |
US60/566,477 | 2004-04-28 | ||
PCT/US2005/014288 WO2005104722A2 (en) | 2004-04-28 | 2005-04-26 | Crude extracts from andrographis paniculata |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020137001151A Division KR101531116B1 (ko) | 2004-04-28 | 2005-04-26 | 천심련으로부터의 조추출물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070033982A true KR20070033982A (ko) | 2007-03-27 |
KR101534844B1 KR101534844B1 (ko) | 2015-07-07 |
Family
ID=35242143
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020137001151A KR101531116B1 (ko) | 2004-04-28 | 2005-04-26 | 천심련으로부터의 조추출물 |
KR1020157010077A KR101536892B1 (ko) | 2004-04-28 | 2005-04-26 | 천심련으로부터의 조추출물 |
KR1020067025043A KR101534844B1 (ko) | 2004-04-28 | 2005-04-26 | 천심련으로부터의 조추출물 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020137001151A KR101531116B1 (ko) | 2004-04-28 | 2005-04-26 | 천심련으로부터의 조추출물 |
KR1020157010077A KR101536892B1 (ko) | 2004-04-28 | 2005-04-26 | 천심련으로부터의 조추출물 |
Country Status (14)
Country | Link |
---|---|
US (3) | US7341748B2 (ko) |
EP (1) | EP1747008B1 (ko) |
JP (1) | JP5221128B2 (ko) |
KR (3) | KR101531116B1 (ko) |
AU (1) | AU2005237550B2 (ko) |
CA (1) | CA2564637C (ko) |
DK (1) | DK1747008T3 (ko) |
ES (1) | ES2534594T3 (ko) |
HU (1) | HUE025117T2 (ko) |
PL (1) | PL1747008T3 (ko) |
PT (1) | PT1747008E (ko) |
RU (1) | RU2383353C2 (ko) |
TW (1) | TWI373340B (ko) |
WO (1) | WO2005104722A2 (ko) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2559614A1 (en) * | 2004-03-11 | 2005-09-22 | Hutchison Medipharma Ltd. | Andrographolide and analogues as inhibitors of tnf.alpha. and il-1.beta.expression |
AU2005237550B2 (en) | 2004-04-28 | 2010-09-23 | Nutrition Science Partners Limited | Crude extracts from andrographis paniculata |
JP2007176934A (ja) * | 2005-11-30 | 2007-07-12 | Kose Corp | 血小板活性化因子アセチルヒドロラーゼ機能調整剤 |
US20070202164A1 (en) * | 2006-02-28 | 2007-08-30 | Hutchison Medipharma Enterprises Limited | Andrographis Extract Formulations |
EP1882473A1 (en) * | 2006-07-28 | 2008-01-30 | Indena S.P.A. | Use of anthocyanosides to prepare formulations for the treatment of mucositis induced by antitumoral drugs |
US20090117209A1 (en) * | 2007-11-02 | 2009-05-07 | Hutchison Medipharma Enterprises Limited | Andrographis paniculata extract |
CN102481284A (zh) * | 2009-03-24 | 2012-05-30 | 新加坡国立大学 | 穿心莲内酯化合物用于治疗炎症和气道病症的用途 |
MD480Z5 (ro) * | 2011-07-07 | 2012-09-30 | Эльвира АНДОН | Metodă de tratament al colitei ulceroase nespecifice acute |
CN102702147B (zh) * | 2012-06-18 | 2016-06-08 | 辽宁利锋科技开发有限公司 | 穿心莲内酯类似物及其治疗的应用 |
CN103145661B (zh) * | 2013-03-25 | 2014-06-18 | 成都天台山制药有限公司 | 穿心莲内酯的新晶型 |
CN103145660B (zh) * | 2013-03-25 | 2014-09-17 | 成都天台山制药有限公司 | 穿心莲内酯及其制备方法 |
CN103223028A (zh) * | 2013-03-27 | 2013-07-31 | 张宗升 | 中药提取物 |
CN103766901A (zh) * | 2014-01-08 | 2014-05-07 | 浙江大学 | 一种穿心莲丙素在制备减肥食品或药品中的应用 |
JP6386761B2 (ja) * | 2014-03-19 | 2018-09-05 | 花王株式会社 | インボルクリン発現抑制剤 |
MY176459A (en) * | 2016-05-23 | 2020-08-10 | Univ Putra Malaysia | Extract of andrographis paniculata for cognitive enhancement |
WO2018081959A1 (en) | 2016-11-02 | 2018-05-11 | Nutrition Science Partners Limited | Extracts of andrographis paniculata, methods for preparation and use thereof |
CN107349253A (zh) * | 2017-06-23 | 2017-11-17 | 苏州凌科特新材料有限公司 | 无刺激医用消毒液及其制备方法 |
WO2022058422A1 (en) * | 2020-09-17 | 2022-03-24 | Dsm Ip Assets B.V. | Use of andrographis paniculata extract to protect against air pollution related diseases |
WO2024092327A1 (pt) * | 2022-10-31 | 2024-05-10 | Mey, Angelica Machado | Composição para obtenção de bioativo natural para terapias oncológicas |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1012941B (zh) | 1989-07-29 | 1991-06-26 | 郭如明 | 穿心莲碱水法新工艺 |
US20030059471A1 (en) | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
JP2000034233A (ja) * | 1998-07-15 | 2000-02-02 | Sumitomo Forestry Co Ltd | 一酸化窒素産生抑制剤 |
JP2001058969A (ja) | 1999-08-20 | 2001-03-06 | Nettairin Saisei Gijutsu Kenkyu Kumiai | 一酸化窒素産生抑制剤 |
PL203216B1 (pl) | 2000-07-28 | 2009-09-30 | Immupharm Aps | Zastosowanie lecznicze hydroksyetylorutozydów, kompozycja farmaceutyczna zawierająca hydroksyetylorutozydy oraz sól Zn²⁺ i/lub kompleks Zn²⁺, zestaw zawierający hydroksyetylorutozydy oraz sól Zn²⁺ i/lub kompleks Zn²⁺, oraz zastosowanie lecznicze kompozycji farmaceutycznej lub zestawu zawierającego hydroksyetylorutozydy oraz sól Zn²⁺ i/lub kompleks Zn²⁺ |
US6629835B2 (en) | 2000-08-01 | 2003-10-07 | Metaproteomics, Llc | Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2 |
US6358526B1 (en) | 2000-08-16 | 2002-03-19 | Rexall Sundown | Method of making tablets and tablet compositions produced therefrom |
US7270835B2 (en) | 2001-06-20 | 2007-09-18 | Metaproteomics, Llc | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
US20030101076A1 (en) | 2001-10-02 | 2003-05-29 | Zaleski John R. | System for supporting clinical decision making through the modeling of acquired patient medical information |
US6753017B2 (en) | 2001-11-07 | 2004-06-22 | Jrs Pharma Lp | Process for preparing dry extracts |
JP2003171301A (ja) | 2001-11-09 | 2003-06-20 | Mahidol Univ | 歯周炎治療における補助剤としてのカルメグゲル |
JP4669920B2 (ja) | 2002-08-21 | 2011-04-13 | 沖縄県 | 血糖上昇抑制且つ血圧上昇抑制作用を有する機能性素材 |
CN1488376A (zh) | 2003-05-09 | 2004-04-14 | 江西诚志信丰药业有限责任公司 | 一种治疗肠道疾病及鼻窦炎的药物胶囊及其制备方法 |
CN1626076B (zh) | 2003-12-11 | 2010-10-06 | 天津天士力制药股份有限公司 | 一种穿心莲内酯滴丸及其制备方法 |
KR101065608B1 (ko) | 2003-12-29 | 2011-09-19 | 주식회사 엘지생활건강 | 안드로그라폴라이드 또는 안드로그라폴라이드를유효성분으로 함유하는 천심련 추출물을 포함하는가려움증 억제 또는 완화 조성물 |
CA2559614A1 (en) * | 2004-03-11 | 2005-09-22 | Hutchison Medipharma Ltd. | Andrographolide and analogues as inhibitors of tnf.alpha. and il-1.beta.expression |
AU2005237550B2 (en) | 2004-04-28 | 2010-09-23 | Nutrition Science Partners Limited | Crude extracts from andrographis paniculata |
EP1758554A1 (en) | 2004-06-12 | 2007-03-07 | Passion For Life Healthcare Limited | Soluble strip for oral or topical adminstration |
CN1628764A (zh) | 2004-08-19 | 2005-06-22 | 贵阳云岩西创药物科技开发有限公司 | 穿心莲制剂及其制备方法 |
US20070202164A1 (en) | 2006-02-28 | 2007-08-30 | Hutchison Medipharma Enterprises Limited | Andrographis Extract Formulations |
US20090117209A1 (en) | 2007-11-02 | 2009-05-07 | Hutchison Medipharma Enterprises Limited | Andrographis paniculata extract |
-
2005
- 2005-04-26 AU AU2005237550A patent/AU2005237550B2/en not_active Ceased
- 2005-04-26 CA CA2564637A patent/CA2564637C/en active Active
- 2005-04-26 PL PL05742174T patent/PL1747008T3/pl unknown
- 2005-04-26 KR KR1020137001151A patent/KR101531116B1/ko active IP Right Grant
- 2005-04-26 DK DK05742174T patent/DK1747008T3/en active
- 2005-04-26 ES ES05742174.5T patent/ES2534594T3/es active Active
- 2005-04-26 KR KR1020157010077A patent/KR101536892B1/ko active IP Right Grant
- 2005-04-26 HU HUE05742174A patent/HUE025117T2/en unknown
- 2005-04-26 WO PCT/US2005/014288 patent/WO2005104722A2/en active Application Filing
- 2005-04-26 JP JP2007510891A patent/JP5221128B2/ja not_active Expired - Fee Related
- 2005-04-26 RU RU2006141834/14A patent/RU2383353C2/ru active
- 2005-04-26 KR KR1020067025043A patent/KR101534844B1/ko active IP Right Grant
- 2005-04-26 EP EP05742174.5A patent/EP1747008B1/en active Active
- 2005-04-26 PT PT05742174T patent/PT1747008E/pt unknown
- 2005-04-27 TW TW094113415A patent/TWI373340B/zh active
- 2005-04-27 US US11/116,678 patent/US7341748B2/en not_active Ceased
-
2010
- 2010-03-04 US US12/717,260 patent/USRE42718E1/en active Active
-
2011
- 2011-07-22 US US13/189,444 patent/USRE43423E1/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20150047645A (ko) | 2015-05-04 |
PT1747008E (pt) | 2015-03-31 |
KR101534844B1 (ko) | 2015-07-07 |
TW200538144A (en) | 2005-12-01 |
JP5221128B2 (ja) | 2013-06-26 |
USRE43423E1 (en) | 2012-05-29 |
EP1747008A4 (en) | 2009-04-22 |
KR101536892B1 (ko) | 2015-07-14 |
TWI373340B (en) | 2012-10-01 |
AU2005237550B2 (en) | 2010-09-23 |
CA2564637C (en) | 2013-09-10 |
USRE42718E1 (en) | 2011-09-20 |
DK1747008T3 (en) | 2015-03-30 |
KR101531116B1 (ko) | 2015-06-23 |
JP2007535542A (ja) | 2007-12-06 |
RU2383353C2 (ru) | 2010-03-10 |
WO2005104722A3 (en) | 2006-03-02 |
PL1747008T3 (pl) | 2015-10-30 |
US20060246156A1 (en) | 2006-11-02 |
US7341748B2 (en) | 2008-03-11 |
HUE025117T2 (en) | 2016-02-29 |
WO2005104722A2 (en) | 2005-11-10 |
EP1747008A2 (en) | 2007-01-31 |
CA2564637A1 (en) | 2005-11-10 |
RU2006141834A (ru) | 2008-06-10 |
KR20130012979A (ko) | 2013-02-05 |
ES2534594T3 (es) | 2015-04-24 |
EP1747008B1 (en) | 2015-01-14 |
AU2005237550A1 (en) | 2005-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101534844B1 (ko) | 천심련으로부터의 조추출물 | |
US7625945B2 (en) | Andrographolide and analogues as inhibitors of TNFα and IL-1β expression | |
AU2008318487B2 (en) | Andrographis paniculata extract | |
JP2016523849A (ja) | 植物組成物とドセタキセルを使用する前立腺癌用併用療法 | |
US20050124684A1 (en) | 5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production | |
JP5816426B2 (ja) | Cgrp応答性抑制剤 | |
KR100889169B1 (ko) | 뉴로키닌-1 수용체 길항 효과를 나타내는 시호 수 추출물의제조 방법 및 시호 수 추출물을 함유하는 뉴로키닌-1수용체 길항성 약학 조성물 | |
KR101667873B1 (ko) | 한방 추출물 또는 이의 분획물을 포함하는 파킨슨 질환의 예방 또는 치료용 약학적 조성물 | |
KR0143719B1 (ko) | 백하수오로부터 추출한 암세포의 다중약제내성조절 작용을 갖는 폴리옥시프레그난 배당체 | |
US20050148616A1 (en) | Inhibitor of TNF-alpha and IL-1beta production | |
KR20190014764A (ko) | 오스문다락톤 및/또는 3,5-디히드록시-감마-카프로락톤을 포함하는 항염증용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E90F | Notification of reason for final refusal | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
B601 | Maintenance of original decision after re-examination before a trial | ||
E801 | Decision on dismissal of amendment | ||
N231 | Notification of change of applicant | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2012101010749; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20121221 Effective date: 20140123 Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20121221 Effective date: 20140123 |
|
J2X1 | Appeal (before the patent court) |
Free format text: TRIAL NUMBER: 2014201001280; APPEAL AGAINST DECISION TO DECLINE REFUSAL Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20141120 Effective date: 20150126 Free format text: TRIAL NUMBER: 2014131000031; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20141120 Effective date: 20150126 |
|
S901 | Examination by remand of revocation | ||
E90F | Notification of reason for final refusal | ||
GRNO | Decision to grant (after opposition) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20180626 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20190625 Year of fee payment: 5 |